Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Fineline Cube Jan 14, 2026
Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Fineline Cube Jan 14, 2026
Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Fineline Cube Jan 14, 2026
Company Deals

Fosun Kairos Inks Vitalgen Tech Deal to Develop In‑Vivo CAR‑T for Autoimmune Diseases

Fineline Cube Jan 14, 2026
Company Deals

Genhouse Bio Raises RMB 300 Million in Cross‑Over Round Led by Green Pine Capital

Fineline Cube Jan 14, 2026
Policy / Regulatory

NHSA Launches 6th VBP Tender for Medical Consumables in China, Targeting Drug-Coated Balloons

Fineline Cube Jan 13, 2026
Company Drug

ImmuneOnco’s IMM2510 Advances to Phase II/III in Endometrial Cancer After Axion Bio Deal Termination

Fineline Cube Jan 14, 2026
Company Drug

Henlius’s HANBEITAI Bevacizumab Biosimilar BLA Accepted by FDA for Multiple Solid Tumors

Fineline Cube Jan 14, 2026
Company Drug

J&J’s SC Amivantamab Faces Complete Response Letter from FDA for NSCLC Treatment

Fineline Cube Dec 17, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has announced that the Biologics License Application (BLA) filed...

Company Drug

Grand Pharmaceutical’s GPN01768 Accepted for Review by NMPA for Demodex Blepharitis Treatment

Fineline Cube Dec 17, 2024

Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced that the National Medical Products Administration...

Company Drug

Jiangsu Hengrui’s Trastuzumab Rezetecan on Track for NMPA’s Breakthrough Therapy Designation

Fineline Cube Dec 17, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Abbisko Therapeutics Receives NMPA Approval for Irpagratinib Regulatory Study

Fineline Cube Dec 17, 2024

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received approval...

Company Drug

Vocabria Receives Positive CHMP Opinion for HIV Treatment in Adolescents

Fineline Cube Dec 17, 2024

GSK plc (NYSE: GSK) has announced that ViiV Healthcare, an HIV specialist majority owned by...

Company Drug

GSK’s Jemperli Receives Positive CHMP Opinion for Endometrial Cancer Indication Extension

Fineline Cube Dec 17, 2024

The UK-based pharmaceutical giant GSK (NYSE: GSK) has received a positive opinion from the European...

Company Drug

GSK’s Jemperli Receives FDA Breakthrough Therapy Designation for Rectal Cancer Treatment

Fineline Cube Dec 17, 2024

UK-based pharmaceutical giant GSK (NYSE: GSK) has announced that it has received Breakthrough Therapy Designation...

Company Drug

CanSino Biologics’ DTcP Vaccine for Infants and Young Children Accepted by NMPA for Review

Fineline Cube Dec 17, 2024

China-based vaccines specialist CanSino Biologics Inc. (HKG: 6185) has announced that the National Medical Products...

Company Deals

MicroPort NeuroTech Leads Investment Fund to Advance Brain Science Industry

Fineline Cube Dec 17, 2024

China-based MicroPort NeuroTech Limited (HKG: 2172) has announced its commitment to invest RMB 200 million...

Company Deals

Candid Therapeutics Expands TCE Portfolio with Strategic Partnerships in Autoimmune Disease Treatment

Fineline Cube Dec 17, 2024

US-based Candid Therapeutics Inc. is fulfilling its ambition to become a leader in advancing T-cell...

Company Drug

EMA Grants PRIME Designation to Hansoh Pharmaceutical’s HS-20093 in Collaboration with GSK

Fineline Cube Dec 17, 2024

The European Medicines Agency (EMA) has conferred Priority Medicines (PRIME) designation to HS-20093 (GSK5764227), a...

Company Deals

Bio-Thera Solutions Expands License Deal with SteinCares for Latin American Market

Fineline Cube Dec 17, 2024

China-based Bio-Thera Solutions (SHA: 688177) has announced the addition of a third biosimilar to its...

Company Drug

European CHMP Supports Conditional Approval of MSD’s Welireg for VHL Disease and RCC

Fineline Cube Dec 16, 2024

Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced that the European Medicines Agency’s Committee...

Company Drug

EMA’s CHMP Recommends Approval of Bayer’s Acoramidis for ATTR-CM Treatment

Fineline Cube Dec 16, 2024

Bayer’s (ETR: BAYN) acoramidis has received a positive recommendation from the Committee for Medicinal Products...

Policy / Regulatory

Guangdong Province Releases List of Urgent Clinical Drugs and Devices for GBA Cities

Fineline Cube Dec 16, 2024

The medical products administration and health commission of Guangdong province have released a list of...

Company Drug

Sanofi’s Tolebrutinib Earns FDA Breakthrough Designation for Non-Relapsing Secondary Progressive MS

Fineline Cube Dec 16, 2024

Sanofi (NASDAQ: SNY) has announced that the US Food and Drug Administration (FDA) has granted...

Company Medical Device

Roche’s cobas 6800/8800 Systems 2.0 Earn CE Certification, Set for US Market Entry

Fineline Cube Dec 16, 2024

Global healthcare company Roche (SWX: ROG) has announced that its state-of-the-art cobas 6800/8800 Systems 2.0...

Company Drug

ARS Pharmaceuticals’ Neffy Receives Market Filings in Asia-Pacific Region

Fineline Cube Dec 16, 2024

US-based ARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has announced that market filings for its intranasal epinephrine...

Company Drug

Fujian Cosunter Pharmaceutical’s GST-HG141 Earns Breakthrough Designation for Chronic Hepatitis B

Fineline Cube Dec 16, 2024

Fujian Cosunter Pharmaceutical Co., Ltd (SHE: 300436), a China-based pharmaceutical company, has announced that it...

Policy / Regulatory

Beijing Conference Outlines 2025 Healthcare Security Goals and 2024 Progress

Fineline Cube Dec 16, 2024

A national conference on healthcare security was recently held in Beijing, reviewing the achievements of...

Posts pagination

1 … 188 189 190 … 609

Recent updates

  • WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities
  • NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development
  • AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D
  • Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund
  • WuXi AppTec Projects 2025 Revenue of $6.51 Billion, Net Profit Surges 103% on Divestments
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company

WuXi Biologics Secures MHRA GMP Certification for Ophthalmic Biologic Manufacturing Facilities

Company Deals

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Company Deals

AstraZeneca Acquires Modella AI to Embed Multi‑Modal Foundation Models in Oncology R&D

Company Deals

Xellsmart Raises RMB 400 M in Series B/B+ and C1 for iPSC Parkinson’s Therapy, Backed by 3SBio and CRHC Fund

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.